Xpovio combo plus mezigdomide to be tested in relapsed-refractory MM
A Phase 1/2 clinical trial will evaluate the safety and efficacy oral mezigdomide, Bristol-Myers Squibb’s investigational treatment, when added to the approved oral…
A Phase 1/2 clinical trial will evaluate the safety and efficacy oral mezigdomide, Bristol-Myers Squibb’s investigational treatment, when added to the approved oral…
Safety and response rates with Abecma (idecabtagene vicleucel) were seen to vary with race in people with relapsed or refractory multiple myeloma (RRMM), but…
A committee of the European Medicines Agency (EMA) has recommended that Elrexfio (elranatamab) — a therapy already in use in the U.S. — be…
While diabetes is more frequent among Black people than white people, it’s associated with poorer survival outcomes in white people with multiple myeloma, a…
People with hard-to-treat multiple myeloma given a regimen of Venclexta (venetoclax) plus dexamethasone lived longer than those treated with Pomalyst (pomalidomide) plus the…
A cell-based vaccine designed to promote immune responses against survivin, a protein that helps tumor cells survive and expand, was found to be safe and…
The Gabrail Cancer Center (GCC) in Canton, Ohio is the first site to open in a Phase 1b clinical trial that’s evaluating STAR-LLD, Starton…
The U.S. has approved BioLineRx’s Aphexda (motixafortide) in combination with filgrastim (G-CSF) to improve the process of autologous hematopoietic stem cell transplant (AHSCT)…
Some multiple myeloma cells acquire mutations that allow them to act in disguise and to escape the effects of T-cell therapies, according to a…
Blood Cancer Awareness Month, observed globally every September, seeks to raise awareness of all blood malignancies — there’s one case of blood cancer diagnosed…